These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 20651188)
21. Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy. Miest TS; Frenzke M; Cattaneo R Mol Ther; 2013 Nov; 21(11):2019-31. PubMed ID: 23913184 [TBL] [Abstract][Full Text] [Related]
22. Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. Penheiter AR; Dingli D; Bender CE; Russell SJ; Carlson SK J Gene Med; 2012; 14(9-10):590-7. PubMed ID: 23015290 [TBL] [Abstract][Full Text] [Related]
23. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772 [TBL] [Abstract][Full Text] [Related]
24. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Mansfield DC; Kyula JN; Rosenfelder N; Chao-Chu J; Kramer-Marek G; Khan AA; Roulstone V; McLaughlin M; Melcher AA; Vile RG; Pandha HS; Khoo V; Harrington KJ Gene Ther; 2016 Apr; 23(4):357-68. PubMed ID: 26814609 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo. Schipper ML; Riese CGU; Seitz S; Weber A; Béhé M; Schurrat T; Schramm N; Keil B; Alfke H; Behr TM Eur J Nucl Med Mol Imaging; 2007 May; 34(5):638-650. PubMed ID: 17160413 [TBL] [Abstract][Full Text] [Related]
26. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Li H; Nakashima H; Decklever TD; Nace RA; Russell SJ Cancer Gene Ther; 2013 Aug; 20(8):478-85. PubMed ID: 23868101 [TBL] [Abstract][Full Text] [Related]
27. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Trujillo MA; Oneal MJ; McDonough S; Qin R; Morris JC Gene Ther; 2010 Nov; 17(11):1325-32. PubMed ID: 20428214 [TBL] [Abstract][Full Text] [Related]
28. Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene. Klutz K; Willhauck MJ; Dohmen C; Wunderlich N; Knoop K; Zach C; Senekowitsch-Schmidtke R; Gildehaus FJ; Ziegler S; Fürst S; Göke B; Wagner E; Ogris M; Spitzweg C Hum Gene Ther; 2011 Dec; 22(12):1563-74. PubMed ID: 21851208 [TBL] [Abstract][Full Text] [Related]
29. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Klutz K; Russ V; Willhauck MJ; Wunderlich N; Zach C; Gildehaus FJ; Göke B; Wagner E; Ogris M; Spitzweg C Clin Cancer Res; 2009 Oct; 15(19):6079-86. PubMed ID: 19789324 [TBL] [Abstract][Full Text] [Related]
30. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050 [TBL] [Abstract][Full Text] [Related]
31. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy. Mitrofanova E; Unfer R; Vahanian N; Link C Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480 [TBL] [Abstract][Full Text] [Related]
32. In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter. Shi S; Zhang M; Guo R; Miao Y; Hu J; Xi Y; Li B PLoS One; 2015; 10(1):e0116531. PubMed ID: 25621996 [TBL] [Abstract][Full Text] [Related]
34. Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus. Grünwald GK; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Göke B; Holm PS; Spitzweg C Gene Ther; 2013 Jun; 20(6):625-33. PubMed ID: 23038026 [TBL] [Abstract][Full Text] [Related]
35. A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer. Trujillo MA; Oneal MJ; McDonough S; Qin R; Morris JC Cancer Gene Ther; 2012 Dec; 19(12):839-44. PubMed ID: 23037808 [TBL] [Abstract][Full Text] [Related]
36. Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter ( Tutter M; Schug C; Schmohl KA; Urnauer S; Schwenk N; Petrini M; Lokerse WJM; Zach C; Ziegler S; Bartenstein P; Weber WA; Wagner E; Lindner LH; Nelson PJ; Spitzweg C Theranostics; 2020; 10(10):4490-4506. PubMed ID: 32292510 [No Abstract] [Full Text] [Related]
37. Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery. Müller AM; Schmohl KA; Knoop K; Schug C; Urnauer S; Hagenhoff A; Clevert DA; Ingrisch M; Niess H; Carlsen J; Zach C; Wagner E; Bartenstein P; Nelson PJ; Spitzweg C Oncotarget; 2016 Aug; 7(34):54795-54810. PubMed ID: 27458162 [TBL] [Abstract][Full Text] [Related]
38. Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter. Huang R; Zhao Z; Ma X; Li S; Gong R; Kuang A Cancer Gene Ther; 2011 Feb; 18(2):144-52. PubMed ID: 21037556 [TBL] [Abstract][Full Text] [Related]
40. Use of rhenium-188 for in vivo imaging and treatment of human cervical cancer cells transfected with lentivirus expressing sodium iodide symporter. Zhang M; Shi S; Guo R; Miao Y; Li B Oncol Rep; 2016 Oct; 36(4):2289-97. PubMed ID: 27573304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]